Dermatology

Into the dermatology clinic sits a sixty-year-old carpenter with a small, shiny papule beside his nasal ala, rimmed with fine telangiectasia, growing slowly for two years, its center occasionally crusting and sloughing — the signature look of basal cell carcinoma. Next door, an old farmer has a keratotic nodule on his lower lip sitting atop a rough, scaly patch; that patch is the precancerous lesion actinic keratosis, and the nodule has already progressed to squamous cell carcinoma. In the next bed, a middle-aged woman has a streak of unevenly pigmented, ragged-bordered darkness beneath her big toenail, its color bleeding into the proximal nail fold — the moment this Hutchinson sign appears, the mood drops instantly, because it is almost certainly subungual melanoma knocking at the door.

The questions on the three great skin cancers really only require fixing the cell of origin first, and the behavior all follows from that. Basal cells have always been the quiet dividers sitting at the very bottom of the epidermis, so the tumors that arise from them are likewise steady and slow — basal cell carcinoma almost never metastasizes to the viscera, and merely excavates, in place, a central ulcer that looks as though a rodent has gnawed it. But if it arises in the H-zone — central face, ears, periocular area — or its histologic subtype is morpheaform or infiltrative, or it has already crept silently along a nerve, then this recurrence-prone, poorly demarcated variant calls for Mohs micrographic surgery, confirming every layer clean under the microscope before stopping. Keratinocytes are the cells whose DNA gets damaged by ultraviolet light, so the forerunner of squamous cell carcinoma is actinic keratosis; this shared origin also explains a direction-reversal question the exam loves to play: actinic keratosis turns into squamous cell carcinoma, not into melanoma, because the cell of origin is the keratinocyte. Reversing this direction is a pit that trips up nearly everyone in the exam hall.

Melanocytes are, by nature, neural-crest descendants born to migrate, so once they turn malignant they travel by both lymphatic and hematogenous routes, and a lesion can be tiny and still lethal. Early screening uses ABCDE — asymmetry, irregular border, mixed color, diameter over six millimeters, evolving over time — but what truly decides prognosis is the tumor's vertical thickness: the thicker it is, the worse the prognosis, and ulceration and mitotic rate also count toward staging, while the older Clark scale, which measured how deep the invasion reached, has since been crowded out to secondary importance. Taiwan and the West differ here in a critically important way: in people of European descent, the most common subtype is superficial spreading, arising on the sun-exposed trunk and limbs; but in East Asia and Taiwan, the most common is instead acral lentiginous melanoma, arising on the palms, soles, and beneath the nails — sites that never see the sun. So that dark streak beneath a toenail must never be dismissed as a stubbed-toe bruise; if the pigment also extends onto the proximal nail fold, that is Hutchinson's sign, and it should raise alarm for subungual melanoma. In advanced-stage treatment, roughly half of cutaneous melanomas carry a BRAF V600E mutation and can be treated with BRAF plus MEK inhibitors; immune checkpoint inhibitors have also dramatically improved survival in advanced disease. But there is one Taiwan-specific exam point: the acral subtype has a lower rate of BRAF mutation, so targeted-therapy data from Europe and North America cannot simply be transplanted onto Taiwanese patients.

As for the remaining benign and precancerous lesions, the traps mostly lie in "directional words." A crater-shaped nodule with a central keratin plug that grows on the face within a few weeks — its histology may look like squamous cell carcinoma, but its speed is the real clue: this is a keratoacanthoma, which may regress spontaneously; excision for confirmation is still advisable, of course, but don't judge it as highly malignant and go straight to radical excision on first sight. A dark red patch present since birth, distributed along the V1 branch of the trigeminal nerve, is a port-wine stain — a benign vascular malformation, not a tumor — though it warrants follow-up for ipsilateral leptomeningeal angioma, glaucoma, and seizures; this Sturge-Weber syndrome is most often wrongly filed under the malignant list as a reversed-direction question. The café-au-lait spots of neurofibromatosis type 1 have thresholds of five millimeters in children and fifteen millimeters in adults, not thirty millimeters — this number, too, is tested year after year.

Three people sit down in the clinic one after another, and in each the skin is speaking for a different organ system. The first is a thirty-two-year-old woman with diabetes whose upper back has grown tighter and tighter, like a rubber mat laid over it, so that she can no longer even pinch up a fold under her bra strap — this induration is telling you that mucopolysaccharide is accumulating in her dermis, that chronic hyperglycemia has glycated her collagen, and that this is scleredema diabeticorum. The second is a twenty-nine-year-old woman with violaceous infiltrated plaques on her nose, cheeks, and ears, her chest film reading bilateral hilar lymphadenopathy — this cluster of granulomas in her skin and the enlarged lymph nodes in her chest are the same story, called sarcoidosis. The third is a four-year-old boy with intensely itchy, poorly demarcated erythema in the antecubital and popliteal fossae, his blood showing both eosinophils and IgE elevated — this spongy edema in his skin is telling you that he is an atopic child, and the diagnosis is atopic dermatitis. Skin does not only grow diseases of its own; it is often the indicator light for disease elsewhere in the body.

To make sense of this matching game, don't treat it as rote memorization. First build the habit of description: keep macule distinct from papule, papule from plaque, nodule from vesicle, and transient edema distinct from all of them, and the differential is already half as narrow. When a question gives you an asymptomatic, thickened, indurated plaque, think deposition and fibrosis; when it gives you a granulomatous nodule, think sarcoidosis, tuberculosis, and deep fungal infection; when it gives you an itchy, weeping red rash, think of the spongiosis family. The core of sarcoidosis is the non-caseating granuloma: macrophages and T cells cluster together but never develop the central caseation seen in tuberculosis; this cluster of granulomas can arise in any organ but favors the mediastinum and the skin, so the most frequently tested link is that cutaneous granuloma plus bilateral hilar adenopathy equals sarcoidosis. Its serum fingerprint is an elevated angiotensin-converting enzyme along with elevated serum and urinary calcium, for a delightfully specific reason: those activated macrophages manufacture their own active vitamin D and push the calcium upward. Löfgren syndrome is the acute triad of bilateral hilar adenopathy, erythema nodosum, and arthritis, and it carries a good prognosis — but watch for one directional trap: erythema nodosum is itself a reactive panniculitis, not a granuloma histologically; it is sarcoidosis's neighbor, not the lesion itself.

Scleredema diabeticorum likewise makes sense once you think the same causal chain through. Chronic hyperglycemia glycates the dermal collagen, mucin piles in on top of it, and the skin turns into a symmetric, asymptomatic induration that, of all places, begins at the central trunk — the upper back, nape, and shoulders — the exact opposite of scleroderma, which begins at the fingertips and comes with Raynaud phenomenon and autoantibodies. This directional question is one of the exam's favorite differentials. Another cutaneous manifestation of diabetes is the yellow-brown atrophic pretibial plaque called necrobiosis lipoidica, which differs from scleredema in both location and texture — don't confuse the two. Whenever you see the word "asymptomatic," raise your guard, because asymptomatic usually signals a deposition-related or metabolic process rather than an inflammatory one, since eczema itches and inflammation hurts.

The pair most easily confused within the red-and-scaly family is eczema and psoriasis. The pathologic core of eczema is edema between epidermal cells: fluid seeps in between the cells like a sponge being forced open by water, so it weeps and it itches. Atopic dermatitis follows exactly this Th2-dominant path — IL-4, -5, and -13 drive up both IgE and eosinophils — and with the barrier gene filaggrin defective, moisture cannot be held in and allergens penetrate easily, so lesions concentrate on the flexor surfaces such as the antecubital and popliteal fossae, are intensely itchy, and relapse chronically. A Th1 and Th17 component blends in during the chronic phase, but the core memory remains Th2, which is why the new drug dupilumab blocks precisely the IL-4 receptor alpha. Keep in mind one point that is easily reversed on the exam: it is eosinophils, not neutrophils, that rise in atopic dermatitis, and an elevated serum IgE is not itself a diagnostic criterion. This also leads into the atopic march: infants first develop atopic dermatitis, and then, in sequence, food allergy, asthma, and allergic rhinitis follow, all sharing the same underlying Th2 and IgE-driven constitution.

Psoriasis takes an entirely different route: T cells drive keratinocyte overproliferation through IL-17, IL-23, and TNF, accelerating epidermal turnover from a normal twenty-eight days down to three or four, so keratinocytes are pushed to the surface before they have matured, piling up dry, silvery-white, thick scale. It carries the familial HLA-Cw6 association, favors the extensor surfaces, scalp, and sacrum, and is sharply demarcated and relatively less itchy. Pinpoint bleeding on scraping the scale is the Auspitz sign, caused by exposure of the dermal papillary capillaries; new lesions arising at sites of scratching or trauma are the Koebner phenomenon; the nails show pitting, like a thimble, and an oil-drop sign. It is associated with psoriatic arthritis, metabolic syndrome, and elevated cardiovascular risk. The treatment ladder runs from topical therapy plus the vitamin D analog calcipotriol, through phototherapy, to systemic methotrexate or cyclosporine or acitretin, and finally to biologics targeting TNF, IL-17, or IL-23. The most dangerous trap is never to control psoriasis with systemic corticosteroids, because abrupt withdrawal rebounds into the pustular form; beta-blockers, lithium, and antimalarials can also trigger or worsen it. Describing eczema as dry with thick silvery scale, describing psoriasis as weeping and intensely itchy, or reversing the flexor and extensor distributions are the most common ways points are lost in this family.

The lower leg holds two more small tales. Stasis dermatitis arises on the lower third of the leg and the medial ankle, because venous hypertension causes blood to pool, the skin to pigment, and the area to feel warm with edema — the exact opposite direction from peripheral artery occlusive disease, which is pale, cold, hairless, and painful. Asteatotic winter eczema, by contrast, is the crazy-paving cracking that appears on elderly patients' shins in winter; management is moisturization — brief lukewarm baths followed immediately by emollient application, avoiding hot water, soap, and excessive bathing — so the answer to a "which is least appropriate" question is usually "soaking in frequent hot baths" or "liberal soap use." The whole chapter strings together into a single sentence: skin never speaks alone — either the epidermis is swelling with edema, or the dermis is accumulating something; look at the level first, then connect it to the system, and the matching game will link itself up.

The moment the high school senior pulls down his mask, his chin and cheeks are a mass of red, swollen nodulocystic lesions plus pigmented scarring, and his mother anxiously asks whether he can use that legendary drug that supposedly cures it for good but causes birth defects. In the next room, a twenty-eight-year-old woman complains of recurrent axillary abscesses for two years — antibiotics knock out one, and another pops up right beside it, leaving sinus tracts and indurated nodules behind. Both of these people have something wrong with their pilosebaceous unit, but they are on completely different paths.

The core of acne is four hands pressing at once: androgens force the sebaceous gland to secrete more oil, abnormal follicular keratinization plugs the pore into a comedone, the anaerobic bacterium Cutibacterium acnes living in the sebum breaks that oil down into inflammatory mediators, and the inflammatory response then pushes the comedone forward into a papule, pustule, or nodulocystic lesion. Treatment must therefore answer each of the four hands with a strike of its own: topical retinoic acid dissolves comedones, benzoyl peroxide is both antibacterial and anti-inflammatory, an oral antibiotic such as doxycycline treats the bacteria, and in severe cases oral retinoic acid shrinks the sebaceous gland itself. The ladder runs from topical therapy alone for mild disease, to adding a topical or oral antibiotic for moderate disease — never as antibiotic monotherapy, to avoid resistance — up to oral retinoic acid for severe nodulocystic disease. This oral retinoic acid is currently the only drug that produces long-term remission of acne, because it shrinks the sebaceous gland at the source, but the cost is that it is a potent teratogen: pregnancy is an absolute contraindication, strict contraception and pregnancy testing are required before and during treatment, and women of childbearing age are enrolled in monitoring like the iPLEDGE program. The most common side effects are cheilitis and mucosal dryness, along with elevated triglycerides and elevated liver enzymes, which require monitoring — and it must never be combined with tetracycline, because both drugs raise intracranial pressure, and combining them can precipitate pseudotumor cerebri, that is, benign intracranial hypertension.

The biggest directional trap in androgenetic alopecia is never to describe it as sudden, massive shedding. Its key feature is a genetically susceptible follicle that, under the action of testosterone converted by 5α-reductase into DHT, gradually miniaturizes — the follicle is still there, just growing thinner and thinner with an ever-shorter growth phase, so it looks sparse and fine rather than falling out in fistfuls. It is gradual and non-scarring. If a question presents it as "acute hair loss," that description is wrong; that kind of sudden, diffuse shedding should point you to stress or the telogen effluvium of two to three months postpartum, while sharply demarcated round patches plus exclamation-point hairs should point you to alopecia areata, an autoimmune form of baldness. Treatment is topical minoxidil to prolong the growth phase and oral finasteride to inhibit 5α-reductase and lower DHT, though it is contraindicated in pregnant women.

The essential nature of hidradenitis suppurativa is frequently misunderstood. Its English name sounds like an infectious disease, but the follicle first occludes, then bursts and spills into the dermis, and the dermis mounts chronic inflammation — the pus is a result of inflammation, not the cause of infection, so plain antibiotics only strike the downstream bacteria and cannot undo the upstream occlusion, which is why new lesions keep erupting. It favors women over men, after puberty, in the apocrine-gland-bearing axillae, groin, perineum, and inframammary folds, with risk factors of obesity, smoking, and family history. The treatment ladder begins with topical and oral antibiotics such as clindamycin paired with rifampin; moderate-to-severe disease, being inflammatory rather than infectious, can be treated with immunosuppression, and the first-choice biologic is adalimumab, an anti-TNF-alpha agent that was first approved in 2015 and remains the standard exam answer; in recent years, the anti-IL-17 agents secukinumab and bimekizumab have also been approved, reflecting IL-17's role in this disease, though exam questions still center on adalimumab. Severe sinus tracts and scarring require surgical excision.

The last small distinction worth sorting out is the definitional difference between hirsutism and hypertrichosis. Hirsutism is male-pattern hair growth, describing coarse dark hair appearing on a woman in androgen-dependent sites such as the upper lip, chin, chest, and midline abdomen, driven by androgen excess, commonly from polycystic ovary syndrome or an adrenal problem. Hypertrichosis is excess hair growth regardless of sex, not confined to any site, and unrelated to androgens; common causes are drugs such as minoxidil, phenytoin, and cyclosporine, along with congenital and paraneoplastic forms. Sort them with one sentence: whether androgen is involved, plus whether the site is androgen-dependent — hold onto these two keywords and you will never swap them. The whole chapter strings together into one line: the pilosebaceous unit has only three main axes — keratinization of sebum, miniaturization of the follicle, and occlusion of the follicle — follow the mechanism, and the treatment ladder arranges itself.

A sixty-eight-year-old man has been breaking out in large blisters over his entire body for two weeks; the blister walls are tense and resist rupture, sitting on an itchy erythematous base, with no mucosal erosion. A fifty-eight-year-old woman is an entirely different story: oral ulcers have made eating too painful for three weeks, and her skin shows flaccid, easily ruptured blisters — the lightest push causes even the seemingly normal skin beside them to slough off as well, Nikolsky sign positive. The dermatology ICU has also admitted a ten-year-old girl who, two weeks after starting carbamazepine, developed high fever, conjunctival erosion, eroded lips, and flaccid blisters rising beneath truncal erythema, with denudation already approaching thirty-five percent — this is toxic epidermal necrolysis, with mortality running in the double digits. The core of every question on blistering skin disease really comes down to one sentence: at what level does the blister split — make that one cut, and the disease name, mechanism, and treatment nearly line themselves up on their own.

From the surface down, the epidermis has roughly a stratum corneum, a stratum spinosum, and a stratum basale, with the basement membrane zone below that connecting to the dermis. A blister can split at three levels. The first level, subcorneal and superficial epidermal, is where staphylococcal scalded skin syndrome, impetigo, and pemphigus foliaceus operate — because it is shallow, the blister wall is thin and ruptures extremely easily. The second level, intraepidermal above the basal layer, is where pemphigus vulgaris operates: the body makes its own IgG antibody against desmoglein 3 plus or minus 1, knocking out the desmosomal proteins between epidermal cells so the cells fall apart from one another — this is acantholysis — and immunofluorescence deposits a net-like pattern of IgG between the epidermal cells; the blister wall is thin, the Nikolsky sign is positive, mucosa is often affected first, and oral ulcers are the classic exam tell. The third level, subepidermal at the basement membrane zone, is where bullous pemphigoid operates: IgG against BP180 and BP230 strikes the hook joining epidermis to dermis, so the blister splits beneath the epidermis, the blister floor is dermis, the blister wall is tense and resists rupture, immunofluorescence shows a linear pattern of IgG and complement C3 along the basement membrane zone, and mucosa is less often affected. The signature of dermatitis herpetiformis is a granular deposit of IgA within the dermal papillae; it is almost always associated with celiac disease, so treatment has two arms — dapsone to control the skin, a gluten-free diet to control the source. Hold onto the four-word mnemonic: shallow and fragile is pemphigus, deep and tense is pemphigoid, and you will never mix up these two diseases separated by a single word.

Pathology vocabulary questions love nothing more than setting traps on the word ending. Parakeratosis is retained nuclei in the stratum corneum, incomplete keratinization, and stands for psoriasis; spongiosis is edema between epidermal cells, sponge-like, and stands for acute eczema and contact dermatitis; acantholysis is loss of adhesion between epidermal cells, with cells detaching, and stands for pemphigus. So never write parakeratosis as hyperkeratosis, or acantholysis as acanthosis — change one part of the word, and the diagnosis flips to its opposite. Among the inflammatory infiltrate patterns is also interface dermatitis, with inflammation concentrated at the epidermal-dermal junction, accompanied by basal vacuolar degeneration and necrotic keratinocytes, linking to lupus erythematosus, lichen planus, and graft-versus-host disease; lichen planus also shows a band-like lymphocytic infiltrate in the superficial dermis hugging the epidermis, producing saw-tooth rete ridges; a granulomatous infiltrate, meanwhile, corresponds to tuberculosis, leprosy, and the non-caseating granuloma of sarcoidosis.

Infection questions have another classic exam tell: whether a pathogen can be cultured from the lesion, and the answer hinges on whether live organisms are actually present in it. The erythema migrans of Lyme disease is the spirochete Borrelia burgdorferi spreading outward from the tick bite site, and live organisms sit right at the expanding erythema's edge, so it can be cultured. Conversely, erythema multiforme, erythema nodosum, and pityriasis rosea are all immune reactions or reactive panniculitis, with no live organism present in the lesion, so cultures come back negative. Be careful: erythema multiforme and erythema migrans sound almost identical but are entirely different diseases — the former is an immune reaction, the latter a spreading spirochete — never swap the two.

What is most worth thinking through in the drug-eruption spectrum is the physical meaning of severity. A drug or its metabolite acts as a hapten to trigger an immune response; at the mild end this is only superficial inflammation that shows up as a morbilliform rash, but the severe end — SJS and TEN — belongs to type IVc, T-cell-mediated cytotoxicity, in which cytotoxic T cells release granulysin, FasL, and perforin, driving keratinocytes throughout the full thickness of the epidermis into apoptosis and separating epidermis from dermis, much like an extensive burn — so what percentage of the body surface area the dead epidermis covers is the very core of grading and prognosis. SJS is under ten percent, overlap runs ten to thirty percent, and TEN is over thirty percent. The seven-item SCORTEN score includes age over forty, heart rate over one hundred twenty, comorbid malignancy, body surface area over ten percent, elevated BUN, elevated glucose, and decreased bicarbonate. The four siblings of severe cutaneous adverse reactions sort by speed: AGEP is fastest, erupting sterile pustules over the whole body within two days along with high fever and leukocytosis; SJS and TEN sit in the middle at one to three weeks; DRESS is slowest, taking two to six weeks to appear, and DRESS also comes with eosinophilia, hepatitis or nephritis, and reactivation of human herpesvirus 6 — this combination of slow onset, visceral involvement, and eosinophilia is its signature. Fixed drug eruption, meanwhile, recurs at the same site with the same drug every single time, leaving pigmentation behind after it heals.

Pharmacogenomics is a must-know topic on Taiwan's exam. Carbamazepine paired with HLA-B*1502 has a high carrier rate in Han Chinese and Southeast Asian populations and carries a high risk of SJS and TEN, so HLA-B*1502 must be screened for before starting the drug; allopurinol pairs with HLA-B*5801 in Han Chinese; abacavir pairs with HLA-B*5701, which is now screened for universally worldwide. Palmoplantar erythema should bring three things to mind: drug allergy, secondary syphilis, and erythema multiforme — syphilis must be confirmed by drawing VDRL and TPPA, so never overlook a history of sexual contact. The pathology of erythema multiforme is interface dermatitis, not dermal fibrosis — this is a wrong answer choice frequently used as a trap — and it is mainly triggered by infection, HSV being most common, so patients with recurrent episodes can be given acyclovir prophylaxis; SJS and TEN, in contrast, are overwhelmingly drug-induced. The most common and potentially fatal management error is treating SJS and TEN like an allergy and flushing them with high-dose corticosteroids; the core of management is actually to stop the drug immediately and provide burn-style supportive care — fluids and electrolytes, temperature, wound care, nutrition, and an ophthalmology consult are all required — while immunomodulation with ciclosporin and the anti-TNF agent etanercept has growing evidence for accelerating re-epithelialization, IVIG and systemic corticosteroids remain controversial, and prophylactic systemic antibiotics should be avoided to prevent resistance. The whole chapter strings together into a single principle: for blistering disease, look at what level the split occurs; for drug eruptions, look at how much epidermis has died — hold onto these two physical quantities, and diagnosis and treatment arrange themselves.

The emergency department receives three patients turning red all over, one after another. The first is a twenty-four-year-old woman who, ten minutes after eating shrimp, breaks out all over in sharply demarcated, intensely itchy wheals, though each one fades within twenty-four hours and leaves no trace. The second is a fifty-five-year-old man on long-term lisinopril for blood pressure control, who wakes in the early morning with his lips and tongue swollen like sausages, not itchy, unresponsive to antihistamines. The third is an eight-year-old boy who, three minutes after his first penicillin injection, develops full-body flushing, a hoarse voice, and a blood pressure that drops to seventy over forty — this is anaphylactic shock, and the lifesaving move is neither an antihistamine nor a corticosteroid, but an intramuscular injection of epinephrine. Questions on redness and swelling sort along only two axes: itchy or not, and whether the reaction is driven by histamine or by bradykinin.

The essential nature of urticaria is mast cell degranulation releasing histamine, causing superficial dermal vessels to dilate and leak and forming a wheal — itchy, sharply demarcated, each individual lesion resolving within twenty-four hours and leaving no trace. If the edema extends deep into the dermis or subcutis, that is angioedema, favoring the eyelids, lips, tongue, and larynx, presenting mainly as swelling and tightness rather than itch. Two frequently tested traps are worth separating clearly. First, if a single wheal persists beyond twenty-four hours, is painful and burning, and leaves bruising or pigmentation behind as it fades, think urticarial vasculitis, a leukocytoclastic vasculitis that requires biopsy to confirm — not simple urticaria. Second, chronic urticaria is defined as symptoms persisting or recurring for six weeks or more, not four weeks, and this number is tested every single year. Chronic urticaria is mostly spontaneous, with roughly half carrying an autoimmune mechanism in which the body produces antibodies against the high-affinity IgE receptor or against IgE itself, which is why it often coexists with autoimmune thyroid disease, and recurrent cases can be screened with anti-TPO and thyroid function tests. The treatment ladder runs with a first line that must be a second-generation, non-sedating antihistamine at standard dose; a second line of increasing the same drug up to four times the standard dose; a third line of adding omalizumab, an anti-IgE monoclonal antibody; and a fourth line of cyclosporine (CsA) or other immunomodulation. The most commonly reversed trap is writing the first line as cyclosporine (CsA) or long-term oral corticosteroids — both wrong, since corticosteroids can only serve as short-term rescue and do not alter the disease course.

The key to differentiating angioedema is whether the dominant mediator is histamine or bradykinin. Histaminergic or allergic angioedema comes with urticaria, is itchy, and responds to both antihistamines and epinephrine; angioedema caused by an angiotensin-converting enzyme inhibitor is entirely different — this class of drug inhibits the very enzyme that breaks down bradykinin, so bradykinin accumulates and the tissue swells, meaning there is no accompanying urticaria and no itch, antihistamines can't touch it, and the drug must be stopped immediately rather than escalating the dose. Hereditary angioedema, meanwhile, involves C1 inhibitor deficiency with low complement C4, no accompanying urticaria, and a positive family history; corticosteroids and antihistamines are both useless, and treatment requires C1 inhibitor replacement, a bradykinin receptor antagonist, or a kallikrein inhibitor. So for that man whose lips and tongue were swollen like sausages with no itch, check his medication history first — if he has been on long-term lisinopril or enalapril, the ACEI must be stopped rather than adding yet more antihistamine. One mnemonic is enough: itch plus a wheal is histamine type; swelling alone with no itch, unresponsive to antihistamines, means think bradykinin, and from there sort out whether it is drug-induced or hereditary.

Last comes penicillin allergy and anaphylactic shock. The most dangerous misconception is assuming that never having had it before means you can't be allergic. Penicillin allergy is an IgE-mediated, immediate-type hypersensitivity; the body may already have been sensitized through environmental exposure or contact with structurally similar compounds, so fatal anaphylactic shock can erupt on the very first clinical dose — meaning no history of allergy is no guarantee of safety. There is only one lifesaving move for treating anaphylactic shock: an intramuscular injection of epinephrine into the lateral thigh, with antihistamines and corticosteroids serving only as adjuncts — they are not what saves the patient's life. The whole chapter distills into one line: when you see redness and swelling, first ask whether it itches, then ask whether it is a wheal or deep edema, then look at the dominant mediator — the histamine type calls for antihistamines and epinephrine, the bradykinin type always calls for stopping the drug or replacing C1 inhibitor first, and saving a patient from anaphylactic shock always means giving epinephrine first, before anything else.

A newborn girl is admitted to the neonatal intensive care unit, her entire body covered in thick, armor-like plates of keratin, deep fissures carving her skin into diamond shapes, both eyelids and lips turned outward, her barrier collapsed, breathing rapid, temperature swinging — this is Harlequin ichthyosis, the gene broken being ABCA12, the transporter responsible for carrying lipids to the stratum corneum. That same week, a twenty-two-year-old man flares in summer, greasy, crusted, foul-smelling keratotic papules erupting across his chest and back, his nails carrying V-shaped notches plus red-and-white streaks — this is Darier disease. In the next bed, a sixty-year-old woman has symmetric brown patches on both cheeks, forehead, and upper lip, darkening in pregnancy — this is melasma. The core of every exam question on inherited skin disease and pigmentary disorders is one sentence: whichever component the gene breaks is the layer where the skin fails; for pigment, ask whether it is gone or in excess, and whether the cell has vanished or merely stopped working.

Ichthyosis tests a broken barrier. The stratum corneum blocks water and pathogens because of this brick wall built from corneocytes plus intercellular lipids. Whichever component fails is the layer where the skin fails. When filaggrin fails, the mortar between corneocytes loosens, the skin turns dry, the barrier fails, and atopic dermatitis comes along with it, because filaggrin is itself an atopy risk gene — which is why the most common form, ichthyosis vulgaris, shares the same gene with atopic dermatitis. X-linked ichthyosis is a steroid sulfatase deficiency, striking males, producing large dark scales, and because the placenta shares the same enzyme, the mother's labor may be delayed at delivery. Lamellar ichthyosis and congenital ichthyosiform erythroderma come from a broken TGM1, presenting at birth as a collodion baby. The most severe is Harlequin, where ABCA12 fails, the stratum corneum is left without lipid, the barrier collapses, and the infant develops thick, armor-like plates with deep fissures and ectropion of the eyelids and lips — historically often fatal. Do not write the collodion baby as Harlequin; the latter is more severe, and its molecule is ABCA12.

Darier disease follows a different path. It arises from an ATP2A2 mutation encoding SERCA2, the endoplasmic reticulum's calcium pump; once calcium signaling is disrupted, desmosome assembly fails, keratinocytes lose their adhesion, and histology shows acantholysis plus dyskeratosis, along with the pathognomonic corps ronds and grains. The most commonly tested reversal is its timing of flares: most ichthyoses fear dryness and worsen in winter, but Darier instead fears heat, sweat, sun exposure, and friction, so it worsens in summer — remember it fears heat, not dryness, and you will never miss this. Its exam partner is Hailey-Hailey disease, whose gene is ATP2C1, encoding the Golgi calcium pump SPCA1; both are autosomal dominant, and both cause acantholysis through a broken calcium pump, but Hailey-Hailey favors the flexures and typically shows neither dyskeratosis nor corps ronds and grains, which is how the two are distinguished.

Water-blister diseases need one more mention. Epidermolysis bullosa's core fact is that it is a genetic disease, not autoimmune — completely different in nature from the autoimmune blistering of pemphigus and pemphigoid — and treatment is supportive only, with no cure. Minor mechanical friction triggers blistering, subtypes are defined by which layer splits, and the deeper the cleavage, the worse the scarring. The simplex type splits within the epidermis, at the basal keratinocyte, with a defect in keratin 5 or 14, mostly autosomal dominant, healing without scarring; the junctional type splits at the lamina lucida, with a defect in laminin-332 or collagen XVII, autosomal recessive, and the severe Herlitz type can be fatal; the dystrophic type splits below the lamina densa, with a defect in collagen VII — the anchoring fibrils — either dominant or recessive, healing with scarring, mitten-hand fusion of the digits, esophageal strictures, and an elevated risk of squamous cell carcinoma. Diagnosis relies on immunofluorescence antigen mapping or transmission electron microscopy to see the cleavage plane and the missing protein, with genetic testing to confirm.

Pigmentary disease has only two exam axes: whether pigment is deficient or excessive, and whether the cell has vanished or is still there. Melanin synthesis proceeds as tyrosine is catalyzed by tyrosinase into DOPA and then into melanin, synthesized inside the melanosome and then transferred to keratinocytes. A break at any step produces an abnormality of pigment. An enzyme deficiency, such as a defective tyrosinase gene, gives albinism — the cell count is normal but cannot make pigment, so it is present from birth, generalized, with nystagmus and photophobia. Cells destroyed and gone give vitiligo, where autoimmunity wipes out melanocytes, producing sharply demarcated milky-white patches that enhance under Wood's lamp, frequently coexisting with autoimmune thyroid disease, type 1 diabetes, and pernicious anemia — which is exactly why it favors this group of patients. Describing vitiligo as reduced melanocyte function is wrong; the cells are destroyed and gone, so remember vanished, not merely disabled. Chemical leukoderma instead comes from occupational chemical exposure — phenol, hydroquinone derivatives, monobenzone, and 4-TBC — poisoning melanocytes, and the key to treatment is removing the source of exposure. Pityriasis alba is fine, depigmented scale on the face of atopic children, a reversible postinflammatory hypopigmentation — never treat it as permanent depigmentation; tinea versicolor, meanwhile, comes from Malassezia producing azelaic acid that inhibits tyrosinase, which is reversible and repigments after treatment.

The mechanism of repigmentation in vitiligo is a small must-know highlight. After phototherapy, small dark dots centered on the hair follicles appear; the pigment comes from the melanocyte precursor reservoir in the outer root sheath, awakened by phototherapy and migrating outward from the follicle — which is why hairless regions such as the fingertips and lips repigment worst, since there is no reservoir to draw from. Treatment includes topical calcineurin inhibitors or corticosteroids, narrowband UVB phototherapy, JAK inhibitors for severe cases, and epidermal grafting once the disease is stable. Melasma, finally, runs in the opposite direction — melanocyte activity is excessive rather than cell number increased — driven by ultraviolet light, female hormones, and genetics, so it appears symmetrically on the cheekbones, forehead, and upper lip, worsening during pregnancy or with oral contraceptives. Treatment addresses these three drivers in turn: strict sun protection is the cornerstone, topical hydroquinone to inhibit tyrosinase is the classic first choice, and Kligman's triple combination plus azelaic acid and tranexamic acid follow for refractory cases, while laser easily causes post-inflammatory darkening and relapse and is reserved for last, used with caution. The whole chapter comes down to one mantra: whichever component the gene breaks decides which layer of the skin fails; for pigmentary disease, first check whether pigment is deficient or excessive, then check whether the cell is still there — follow the mechanism, and the diagnosis surfaces on its own.